EuroBiotech: More Articles of Note

(Image: NS Newsflash/CC BY 2.0)

> The Bill & Melinda Gates Foundation awarded CureVac grants to support development of mRNA vaccines against influenza and malaria. The foundation agreed to support CureVac’s work in the area as part of its equity investment in 2015. Statement

> Affimed laid out a stock offering designed to net it $21.6 million. Release

> Verona Pharma provided more detail on the timing of upcoming clinical trial readouts. The British drug developer expects to have phase 2b COPD data early in the second quarter and top-line phase 2a cystic fibrosis data late in the first quarter. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Merus filed to raise $55.8 million in a private stock offering. Biotechnology Value Fund, Aquilo, Sofinnova and LSP snapped up the stock at a 9% premium. Release

> The FDA cleared DBV Technologies to file for approval of its peanut allergy drug on the basis of data from its failed phase 3 trial. DBV said the agency agreed it has the data to support a submission. Statement 

> Shares in Galmed tanked after the Israeli biotech’s SCD1 modulator missed the mark in a phase 2 NAFLD trial. Release

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.